Matthew K Fust
CIK 1397266 · EVP & Chief Financial Officer · last filed 2026-09-01
Matthew K Fust is an EVP & Chief Financial Officer who has filed 128 SEC Form 4 insider transactions across 8 companies since 2007. The most recent filing shows the insider disposed of $2.4M of CRNX on Sep 1, 2026. Across all open-market trades the lifetime net is −$14.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $13.0M across reported positions. 24 SEC filings were submitted jointly with Ultragenyx Pharmaceutical Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ONXX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
60 LEVERONI COURT
NOVATO, CA 94949
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Director | 5,925 | $84.95 | $503.3K | -$3.70M | 18 | 2026-09-01 |
| ATRA | Director | 30,188 | $8.35 | $252.1K | -$795.7K | 28 | 2026-06-11 |
| NMRA | Director | 27,839 | $0.39 | $10.9K | -$371.0K | 6 | 2026-05-29 |
| RARE | Director | 33,696 | $16.08 | $541.8K | -$2.21M | 22 | 2026-05-18 |
| DERM | Director | 5,051 | $4.97 | $25.1K | -$88.0K | 12 | 2019-12-26 |
| MGNX | Director | 7,424 | $2.19 | $16.3K | -$203.4K | 7 | 2019-05-20 |
| ONYX PHARMACEUTICALS INC (ONXX) Delisted | EVP & Chief Financial Officer | 40,303 | — | — | -$7.05M | 23 | 2013-08-12 |
| JAZZ | EVP, Chief Financial Officer | 58,948 | $205.70 | $12.13M | $0 | 5 | 2008-12-01 |
Recent Filings
128 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-01 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Disp (D) | −28,761 | -$2.44M | EDGAR |
| 2026-06-22 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Grant (A) | +5,925 | $0 | EDGAR |
| 2026-06-11 | ATRA | Grant (A) | +12,000 | $0 | EDGAR |
| 2026-05-29 | NMRA | Grant (A) | — | $0 | EDGAR |
| 2026-05-18 | RARE | Grant (A) | +7,751 | $0 | EDGAR |
| 2025-09-30 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Mixed | −6,000 | -$696.9K | EDGAR |
| 2025-09-26 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Notice (144) | −16,000 | -$574.2K | EDGAR |
| 2025-06-13 | Crinetics Pharmaceuticals, Inc. (CRNX) Delisted | Grant (A) | +6,900 | $0 | EDGAR |
| 2025-06-12 | ATRA | Grant (A) | +7,828 | $0 | EDGAR |
| 2025-05-30 | NMRA | Mixed | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.